Use the hyperlinks, where available to access additional clinical trial information.
A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL
This is a non-randomised, open label study in which, in part 1 of the study, eligible participants will receive sequential doses of oral GSK3368715 once daily. In part 2 of the study, eligible participants will receive the recommended dose of oral GSK3368715, as determined in part 1 of the study. Participants that have been diagnosed with pancreatic cancer (unresectable, locally advanced (Stage III), or metastatic (Stage IV) disease; relapsed or refractory disease after at least 1 prior line of systemic therapy), Non-Small Cell Lung Cancer ((NSCLC) stage IV disease) or urothelial carcinoma (unresectable, locally advanced (T4b) or metastatic (lymph node or visceral) disease; relapsed or refractory disease after at least 1 prior line of systemic therapy), will be eligible for inclusion in part 2 of the study.